Pharmacoeconomic Evaluation of PD-L1 Receptor Inhibitors for the Second Line Treatment of Metastatic Non-Small Cell Lung Cancer

Medical Technologies. Assessment and Choice
doi 10.31556/2219-0678.2018.32.2.067-080
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Fund Gelios


Related search